Connect your AI

Cytokinetics CYTK CA — Additional Lease Agreement Allowances For Tenant Improvements

Discontinued — last reported Q1 '21

Similar metrics at other companies

ARWRCalifornia — Maximum additional tenant improvement allowance

$7.2M-69.5%

ARWRCalifornia — Proceeds From Tenant Improvement Allowance

$3.1M0.0%

ARWRCA — Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances

$4.2M—

ARWRCalifornia — Additional tenant improvement allowance liability

$3.1M-88.8%

EXELAlameda California — Tenant Lease Improvements Allowance

$1.7M—

ARWRCalifornia — Additional tenant improvement allowance interest per annum

7%-2.0pp

Other financials

Income statement

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept cytk:AdditionalLeaseAgreementAllowancesForTenantImprovements.

The official record: Cytokinetics’s 10-K, filed February 26, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does CA — additional lease agreement allowances for tenant improvements mean?: Extra funds provided by landlords to cover the cost of customizing leased California facilities.
How do you interpret CA — additional lease agreement allowances for tenant improvements?: Higher allowances reduce the company's capital expenditure burden for facility development.
How does CA — additional lease agreement allowances for tenant improvements compare across companies?: Common in biotech where high-cost specialized lab build-outs are required.